GeneCopoeia ACE2 and lung stable cell lines for COVID-19 research

GeneCopoeia offers collections of cell lines expressing human host factors needed for SARS-CoV-2 infection as well as labelled cancer cell lines, which include five lung cancer cell line derivatives.

Angiotensin-converting enzyme 2 (ACE2) has been identified as a functional receptor for SARS-CoV1 and a potent receptor for 2019-nCoV2. ACE2 is a carboxypeptidase that potently degrades angiotensin II to angiotensin 1–7, playing a key role in the renin-angiotensin system (RAS). GeneCopoeia carries a HEK293T cell line expressing ACE2, the receptor needed for SARS-CoV-2 infection in humans.

In addition to the ACE2 stable cell line, the company also offers lung cancer cell lines, which contain both firefly luciferase and GFP or GFP alone, integrated into the genome. These are valuable for COVID-19 coronavirus research since the SARS-CoV-2 virus enters the body via lung epithelial cells, and can be used for drug target identification and compound screening either in vitro or in vivo.